非球面有晶状体眼人工晶状体植入矫正近视的安全性和有效性:短期临床结果
前瞻性多中心单盲随机对照研究纳入187例(187只眼)近视患者,比较非球面PR型PIOL与V4c型ICL术后6个月效果。两组有效性指数、安全性指数及视力差异均无统计学意义,试验组主要终点达标率非劣效于对照组,术后1个月眩光发生率试验组低于对照组,6个月内两组均无术后并发症。
要点
- 术后6个月试验组与对照组有效性指数分别为1.12±0.24和1.14±0.21,安全性指数分别为1.28±0.26和1.26±0.23,组间差异均无统计学意义(均P>0.05)。
- 主要终点达标率试验组98.81%(83/84) vs 对照组100%(86/86),差值为-1.19%,绝对值小于非劣效界值10%,试验组非劣效于对照组。
- 术后1个月眩光发生率试验组24.72%(22/89)低于对照组54.26%(51/94)(P<0.05);6个月随访两组均无术后并发症。
核心结论
- 非球面PIOL植入术矫正近视眼术后短期(术后6个月)具有良好的安全性和有效性,且术后早期视觉质量较高。
- 原文结论指出其长期安全性和有效性需要进一步随访验证。
研究设计与样本
- 前瞻性、多中心、单盲(盲患者)、随机对照临床研究,2019年3月至2022年4月在包括复旦大学附属眼耳鼻喉科医院眼科、首都医科大学附属北京同仁医院北京同仁中心等9家眼科医疗机构开展。
- 纳入拟行PIOL植入术的近视眼患者,采用中央动态随机系统分为试验组(植入非球面PR型PIOL)和对照组(植入V4c型植入式Collamer透镜)。
- 共纳入187例(187只眼)患者,男性47例(47只眼),女性140例(140只眼),年龄(28.60±5.08)岁(范围25~32岁);试验组91例(91只眼),对照组96例(96只眼)。
- 术后1、3、6个月比较有效性指数、安全性指数、裸眼远视力、裸眼近视力、最佳矫正远视力、拱高、眼压、角膜内皮细胞密度、视觉症状及并发症,主要终点为术后6个月有效性指数达到0.8的患者人数百分比。
- 采用独立样本t检验、卡方检验等进行统计学分析。
主要发现
- 术后6个月有效性指数试验组1.12±0.24 vs 对照组1.14±0.21,安全性指数试验组1.28±0.26 vs 对照组1.26±0.23,组间差异均无统计学意义(均P>0.05)。
- 主要终点达标率试验组98.81%(83/84) vs 对照组100%(86/86),差值为-1.19%,绝对值小于非劣效界值10%,试验组非劣效于对照组。
- 术后6个月裸眼远视力试验组-0.01±0.09 logMAR vs 对照组-0.03±0.08 logMAR,最佳矫正远视力试验组-0.06±0.07 logMAR vs 对照组-0.08±0.06 logMAR,组间差异均无统计学意义(均P>0.05)。
- 眼压和角膜内皮细胞密度组间差异均无统计学意义(均P>0.05);术后1和6个月中央拱高及周边拱高与中央拱高差组间差异均有统计学意义(均P<0.05),周边拱高组间差异无统计学意义(P>0.05)。
- 术后1个月眩光发生率试验组24.72%(22/89)低于对照组54.26%(51/94)(P<0.05);复视、重影、模糊等视觉症状两组发生率相当,差异均无统计学意义(均P>0.05);6个月随访中两组均未出现术后并发症。
关键数值与推荐
- 非劣效界值为-10%,主要终点达标率差值-1.19%的绝对值小于该界值,试验组非劣效于对照组。
- 有效性指数达标阈值定义为0.8,主要终点为术后6个月有效性指数达到0.8的患者人数百分比。
临床怎么用
- 原文结论认为非球面PIOL植入术矫正近视眼术后短期(术后6个月)具有良好的安全性和有效性,且术后早期视觉质量较高。
- 原文结论指出其长期安全性和有效性需要进一步随访验证。
局限性
- 原文结论指出长期安全性和有效性需要进一步随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the clinical safety and efficacy of aspheric phakic intraocular lens (PIOL) implantation for myopia correction. Methods: This prospective, multicenter, single-blind (patient-masked), randomized, controlled clinical trial was conducted from March 2019 to April 2022 across nine ophthalmic centers (including the Eye & ENT Hospital of Fudan University and Beijing Tongren Hospital, Capital Medical University). Eligible myopic patients scheduled for PIOL implantation were randomly assigned via a centralized dynamic randomization system to receive either the experimental aspheric PR PIOL or the control V4c implantable Collamer lens. At postoperative 1, 3, and 6 months, the efficacy index (primary endpoint: proportion achieving≥0.8 at 6 months), safety index, uncorrected distance/near visual acuity, best-corrected distance visual acuity, vault, intraocular pressure, corneal endothelial cell density, visual symptoms, and complications of the two groups were compared, with statistical analyses using the independent t-tests and chi-square tests. Results: The study enrolled 187 myopic patients (187 eyes), including 47 males (47 eyes) and 140 females (140 eyes), with a mean age of (28.60±5.08) years (range: 25 to 32 years). The experimental group included 91 patients, while the control group included 96 patients. At 6 months postoperatively, the efficacy index was 1.12±0.24 and 1.14±0.21, and the safety index was 1.28±0.26 and 1.26±0.23 in the experimental group and the control group, respectively, with no statistically significant differences between the two groups (both P>0.05). The difference in primary endpoint achievement rates was -1.19% [98.81% (83/84) in the experimental group vs. 100% (86/86) in controls], which exceeded the non-inferiority margin of -10%, demonstrating non-inferiority of the experimental intervention. At 6 months, the experimental group demonstrated uncorrected distance visual acuity of -0.01±0.09 logMAR compared to -0.03±0.08 logMAR in the control group, while best-corrected distance visual acuity was measured at -0.06±0.07 logMAR versus -0.08±0.06 logMAR, with no statistically significant differences observed between groups (both P>0.05). Similarly, there were no statistically significant intergroup differences in intraocular pressure and corneal endothelial cell density (both P>0.05). At both 1 month and 6 months postoperatively, the differences were significant between the two groups in the central vault and the peripheral-central vault difference (all P<0.05); however, no statistically significant difference in the peripheral vault was observed between groups (both P>0.05). At 1 month postoperatively, the incidence of glare in the experimental group [24.72% (22/89)] was significantly lower than that in the control group [54.26% (51/94)] (P<0.05). And there were no statistically significant differences between the two groups in the incidence of other visual symptoms including diplopia, ghosting, and blurred vision (all P>0.05). During the 6-month follow-up period, neither group exhibited any postoperative complications. Conclusion: Aspheric PIOL implantation shows favorable 6-month safety/efficacy and visual quality in myopia correction, though long-term outcomes warrant further investigations. 目的: 评价非球面有晶状体眼人工晶状体(PIOL)用于近视眼矫正手术的安全性和有效性。 方法: 前瞻性多中心单盲(盲患者)随机对照临床研究。2019年3月至2022年4月在复旦大学附属眼耳鼻喉科医院眼科、首都医科大学附属北京同仁医院北京同仁中心等9家眼科医疗机构纳入拟行PIOL植入术的近视眼患者,采用中央动态随机系统分为试验组[植入非球面PR(phakic refractive)型PIOL]和对照组(植入V4c型植入式Collamer透镜),检查并比较2个组术后1、3、6个月的有效性指数和安全性指数、裸眼远视力(UDVA)、裸眼近视力、最佳矫正远视力(BCDVA)、拱高、眼压、角膜内皮细胞密度、视觉症状以及并发症等(以最小分辨角的对数记录视力),以及主要终点指标(术后6个月的有效性指数达到0.8的患者人数百分比)。采用独立样本t检验、卡方检验等进行统计学分析。 结果: 共纳入187例(187只眼)近视眼患者,男性47例(47只眼),女性140例(140只眼);年龄为(28.60±5.08)岁(范围为25~32岁)。试验组91例(91只眼)患者,对照组96例(96只眼)患者。术后6个月,试验组和对照组的有效性指数分别为1.12±0.24和1.14±0.21,安全性指数分别为1.28±0.26和1.26±0.23,组间比较差异均无统计学意义(均P>0.05);试验组[98.81%(83/84)]与对照组[100%(86/86)]的有效性主要终点指标差为-1.19%,其绝对值小于非劣效界值10%,试验组非劣效于对照组。术后6个月,试验组和对照组的UDVA分别为-0.01±0.09和-0.03±0.08,BCDVA分别为-0.06±0.07和-0.08±0.06,组间比较差异均无统计学意义(均P>0.05);眼压和角膜内皮细胞密度的组间比较差异均无统计学意义(均P>0.05)。术后1和6个月,中央拱高以及周边拱高与中央拱高差试验组与对照组的差异均有统计学意义(均P<0.05);周边拱高试验组与对照组的差异无统计学意义(P>0.05)。术后1个月,试验组眩光的发生率[24.72%(22/89)]低于对照组[54.26%(51/94)],差异有统计学意义(P<0.05),复视、重影、模糊等视觉症状2个组的发生率相当,差异均无统计学意义(均P>0.05)。在术后6个月的随访中,2个组均未出现术后并发症。 结论: 非球面PIOL植入术矫正近视眼,术后短期(术后6个月)具有良好的安全性和有效性,且术后早期视觉质量较高;其长期安全性和有效性需要进一步随访验证。.
引用
- Wang XY, Dong Z, Xiong Y, et al. [Safety and efficacy of aspheric phakic IOL implantation in myopia: short-term clinical results]. Zhonghua Yan Ke Za Zhi. 2025. PMID: 41073322. doi:10.3760/cma.j.cn112142-20250421-00192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。